Over the last couple of decades bioprocessing has used its existing technologies as efficiently as possible. However, with a newer toolbox of options to intensify downstream manufacturing operations now available, it is important to understand what factors should impact your decisions regarding the implementation of these innovative solutions.
Continuous manufacturing is a key step toward promoting drug quality and improving manufacturing efficiency, which could ultimately lead to lower drug prices. Breaking down the implementation of continuous manufacturing into the four steps outlined here may provide some much-needed guidance as you prepare your network for the future of biomanufacturing.
Biomanufacturers are continuously looking for ways to improve process efficiency to cost-effectively reduce risk in an increasingly fragmented global market. Meeting the goals of today’s industry requires a deeper look at how to achieve maximum utilization and reduce waste without sacrificing quality in the race to be first to market.
Innovation is on the rise in biopharma in both the molecules pursued and the facilities and equipment used to develop them. Achieving “smarter,” more flexible workflows requires a complete understanding of today’s novel solutions and technologies, which, when applied appropriately, can push the boundaries of drug development and offer critical advantages in an increasingly competitive industry.
Increasing the integration of upstream and downstream processing and moving toward increased automation results in greater optimization of process efficiency — a key goal for biopharma production. Learn how several different approaches and technologies can improve the efficiency of upstream processing, including cell line development, process development and process intensification, real-time analytics, and process integration.